Immuneering Stock (NASDAQ:IMRX)
Previous Close
$6.04
52W Range
$1.10 - $10.08
50D Avg
$6.43
200D Avg
$3.25
Market Cap
$228.70M
Avg Vol (3M)
$1.78M
Beta
0.47
Div Yield
-
IMRX Company Profile
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NTHI | Neonc Technologies Holdings, Inc. |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. |
| SLS | SELLAS Life Sciences Group, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| PYXS | Pyxis Oncology, Inc. |
| CDXS | Codexis, Inc. |
| TARA | Protara Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| TRDA | Entrada Therapeutics, Inc. |
| SAVA | Cassava Sciences, Inc. |